Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Significance, Mechanism of Action, and New Targeted Drug Research of DKK2 Protein in Cerebral Ischemia-reperfusion Injury

NCT05585255 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT05585255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05585255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Significance, Mechanism of Action, and New Targeted Drug Research of DKK2 Protein in Cerebral Ischemia-reperfusion Injury
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2022
Completion date
September 30, 2024
Enrollment
108 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral edema, ischemia-reperfusion injury, ischemic stroke, acute